These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16262214)

  • 21. Watchful waiting for prostate cancer: a review article.
    Chodak GW; Warren KS
    Prostate Cancer Prostatic Dis; 2006; 9(1):25-9. PubMed ID: 16402090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.
    Joslyn SA; Konety BR
    Urology; 2006 Jul; 68(1):121-5. PubMed ID: 16806432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
    Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns CF; Navani S; Armstrong J
    Prostate Cancer Prostatic Dis; 2007; 10(1):87-93. PubMed ID: 17102802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE.
    Arredondo SA; Downs TM; Lubeck DP; Pasta DJ; Silva SJ; Wallace KL; Carroll PR
    J Urol; 2008 May; 179(5 Suppl):S14-8. PubMed ID: 18405740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
    J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Words of wisdom. Re: Radical prostatectomy versus watchful waiting in early prostate cancer.
    Cooperberg MR
    Eur Urol; 2011 Oct; 60(4):868-9. PubMed ID: 21878196
    [No Abstract]   [Full Text] [Related]  

  • 31. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort.
    Mucci LA; Pawitan Y; Demichelis F; Fall K; Stark JR; Adami HO; Andersson SO; Andrén O; Eisenstein AS; Holmberg L; Huang W; Kantoff PW; Perner S; Stampfer MJ; Johansson JE; Rubin MA
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):249-51. PubMed ID: 18199732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting.
    Berge V; Thompson T; Blackman D
    Eur Urol; 2007 Oct; 52(4):1036-43. PubMed ID: 17178188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial.
    Schulz RJ; Kagan AR
    J Natl Cancer Inst; 2009 Jan; 101(2):124. PubMed ID: 19141784
    [No Abstract]   [Full Text] [Related]  

  • 38. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.
    Puech P; Potiron E; Lemaitre L; Leroy X; Haber GP; Crouzet S; Kamoi K; Villers A
    Urology; 2009 Nov; 74(5):1094-9. PubMed ID: 19773038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Korfage IJ
    Eur Urol; 2009 Feb; 55(2):432. PubMed ID: 18783875
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.